Filtered By:
Vaccination: Ebola Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 123 results found since Jan 2013.
The U.S. Scientist At the Heart of COVID-19 Lab Leak Conspiracies Is Still Trying to Save the World From the Next Pandemic
Ralph Baric stepped onto the auditorium stage at the University of North Carolina, Chapel Hill, and looked out at the sparse audience that had come to hear him speak. On the large projector screen hanging behind him, the following words appeared: How Bad the Next Pandemic Could Be, What Might It Look Like, and Will We be Ready. The date was May 29, 2018.
“Well, I have to admit I’m a little worried about giving this talk,” Baric said. “The reason is being labelled a harbinger of doom.” The screen shifted, and images of the four horsemen of the apocalypse—Death, Famine, War, and Plague&mda...
Source: TIME: Health - July 11, 2023 Category: Consumer Health News Authors: Dan Werb Tags: Uncategorized COVID-19 feature freelance Source Type: news
Dr. Anthony Fauci Is Stepping Down. Here ’s His Advice For His Successor
After Dr. Anthony Fauci steps down as head of the National Institute of Allergy and Infectious Diseases (NIAID) and chief medical advisor to President Biden on Dec. 31, he’ll leave behind a long and storied career. Ahead of his last day, he spoke to TIME from his office at the National Institutes of Health about what’s next for him—and his advice for whoever fills his shoes.
This interview has been edited and condensed for clarity.
TIME: You’re leaving your leadership positions in the federal government, but you aren’t retiring. What are you calling the next stage in your career?
[time-brightc...
Source: TIME: Health - December 20, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
U.S. weighs crackdown on experiments that could make viruses more dangerous
.news-article__hero--featured .parallax__element{ object-position: 50% 40%; -o-object-position: 50% 40%; } .scroll-wrapper { overflow-x: auto; } .scroll-wrapper .news-article__figure__image{ width: 2680px; max-width: none; padding-bottom: .75rem; } .scroll-fade-before, .scroll-fade-after { position: absolute; width: 1.5rem; transition-duration: .1s; opacity: 1; } .scroll-fade-before { left: 1rem; /*margin-left: -1px;*/ background: linear-gradient(90deg, #fff, #fff 35%, hsla(0, 0%, 100%, 0)); } .scroll-fade-after { right: 1rem; /*margin-right: -1px;*/ background: linear-gradient(270deg, #fff, #fff 35%, hsla(0,...
Source: ScienceNOW - October 19, 2022 Category: Science Source Type: news
Scientists race to test vaccines for Uganda ’s Ebola outbreak
A multipronged international effort has begun to pull out all the stops to launch trials of experimental Ebola vaccines in Uganda, which declared an outbreak of the deadly disease on 20 September. According to the most recent World Health Organization (WHO) update, Uganda has had 18 confirmed and 18 suspected cases of Ebola, including 23 deaths—an unusually high case fatality rate of 64%. A trial of a vaccine candidate that’s farthest along in development could launch before the end of next month.
Proven vaccines exist for Zaire ebolavirus, which has led to a dozen outbreaks in the neighboring Democratic Republic ...
Source: ScienceNOW - September 29, 2022 Category: Science Source Type: news
News at a glance: New gene therapy, Europe ’s drought, and a black hole’s photon ring
ARCHAEOLOGY
Drought exposes ‘Spanish Stonehenge’ for study
Scientists are rushing to examine a 7000-year-old stone circle in central Spain that had been drowned by a reservoir for decades and was uncovered after the drought plaguing Europe lowered water levels. Nicknamed the “Spanish Stonehenge”—although 2000 years older than the U.K. stone circle—the Dolmen of Guadalperal (above) was described by archaeologists in the 1920s. The approximately 100 standing stones, up to 1.8 meters tall and arranged around an oval open space, were submerged in the Valdecañas reservoir after the construction of a ...
Source: Science of Aging Knowledge Environment - August 25, 2022 Category: Geriatrics Source Type: research
He battled AIDS, COVID-19, and Trump. Now, Anthony Fauci is stepping down
Anthony Fauci, the renowned physician-scientist who has led the $6.3 billion National Institute of Allergy and Infectious Diseases (NIAID) for nearly 4 decades and since early 2020 has been the U.S. government’s voice of scientific reason during the COVID-19 pandemic, will step down from government service in December.
Fauci, 81, had said in
recent interviews
that he planned to retire from the government by the end of President Joe Biden’s administration, but did not give a date until today. He said in a
statement
that although leading NIAID “has been the honor of a lifetime,” he plans to “pursue...
Source: Science of Aging Knowledge Environment - August 22, 2022 Category: Geriatrics Source Type: research
Ebola vaccine being used in Congo produces lasting antibody response, study finds
FINDINGSA new study by UCLA researchers and colleagues demonstrates that the Ebola vaccine known as rVSV ΔG-ZEBOV-GP results in a robust and enduring antibody response among vaccinated individuals in areas of the Democratic Republic of Congo that are experiencing outbreaks of the disease. Among the more than 600 study participants, 95.6% demonstrated antibody persistence six months after they received the vaccine.The study is the first published research examining post –Ebola-vaccination antibody response in the DRC, a nation of nearly 90 million. While long-term analyses of the study cohort continue, the findings will ...
Source: UCLA Newsroom: Health Sciences - February 8, 2022 Category: Universities & Medical Training Source Type: news
Statement on Data Published in PLOS Medicine on Tolerability and Immune Response of Johnson & Johnson Ebola Vaccine Regimen in Adults Living with HIV
NEW BRUNSWICK, N.J., October 29, 2021 – Data published in PLOS Medicine demonstrated that the Johnson & Johnson (the Company) Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), was well tolerated and induced a robust immune response in both healthy adults and adults living with HIV. These findings, alongside Phase 3 data recently published in The Lancet Infectious Diseases, support the potential prophylactic use of the vaccine regimen to protect people at risk of acquiring Ebola. The regimen was granted Marketing Authorisation by the European Commission in July 2020 and Prequalification from th...
Source: Johnson and Johnson - October 29, 2021 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Ebola Vaccine Regimen Demonstrated Robust and Durable Immune Response in Adults and Children in Data Published in The Lancet Infectious Diseases
NEW BRUNSWICK, N.J., September 13, 2021 – Data from two papers published in The Lancet Infectious Diseases demonstrated that the Johnson & Johnson (the Company) Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), generated robust humoral (antibody) immune responses in adults and children (ages 1-17) with the immune responses persisting in adults for at least two years. The data also showed that booster vaccination with Ad26.ZEBOV, administered to adults two years after the initial vaccination, induced a strong anamnestic (immune) response within seven days. These findings support the potential p...
Source: Johnson and Johnson - September 13, 2021 Category: Pharmaceuticals Source Type: news
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
NEW BRUNSWICK, N.J., July 1, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted today to bioRxiv. “Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help prot...
Source: Johnson and Johnson - July 1, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa
Discussions are ongoing with the U.S. Food and Drug Administration regarding the approval of the vaccine regimen in the U.S. WHO Prequalification is often a prerequisite for national registrations of new vaccines and medicines in developing countries. Johnson & Johnson now looks forward to collaborating with the WHO’s African Vaccine Regulatory Forum (AVAREF) to progress national registrations of the Company’s Ebola vaccine regimen. The Company’s Ebola vaccine regimen is designed to be used proactively to induce immunity against Ebola virus disease in adults and children. Johnson & Johnson’s Commitment to E...
Source: Johnson and Johnson - May 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson & Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson & Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participants ...
Source: Johnson and Johnson - April 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents
New Brunswick, NJ (April 2, 2021) – Johnson & Johnson (the Company) has begun vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. “The COVID-19 pandemic has had a profound impact on adolescents, not just with the complications of the disease, but with their education, mental health, and wellbeing,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “It is vital that we develop vaccines for everyone, everywher...
Source: Johnson and Johnson - April 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
The year's new drugs and biologics 2020
Drugs Today (Barc). 2021 Feb;57(2):101-177. doi: 10.1358/dot.2021.57.2.3275929.ABSTRACT2020 will go down in history as a year marked in every respect by the emergence and astonishingly rapid spread of the first major global viral pandemic in a century. It seems like nearly every event or story of the year was influenced in some way by COVID-19, and in that respect, the year ended on a high note with the authorization for emergency use of the first vaccines to prevent SARS-CoV-2 infection and drugs to treat COVID-19. Despite the pandemic's dominance of the 2020 headlines, productivity was at a record high level across all t...
Source: Drugs of Today - March 3, 2021 Category: Drugs & Pharmacology Authors: A I Graul L A Sorbera Source Type: research
